Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | CCR3 | P51677 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328504 | 0.95 | OPRL1 (0.70) | OPRL1POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL2360601 | 0.95 | OPRL1 (0.70) | OPRL1POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL350525 | 0.92 | OPRL1 (0.65) | OPRL1POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL2323985 | 0.89 | OPRL1 (0.73) | OPRL1POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL11195174 | 0.88 | OPRL1 (0.77) | OPRL1POLBOPRM1CCR3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL11193622 | 0.87 | OPRL1 (0.75) | OPRL1POLBOPRM1CCR3SIGMAR1 | |
| SCHEMBL6913288 | 0.86 | OPRL1 (0.70) | OPRL1POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL6911078 | 0.84 | OPRL1 (0.71) | OPRL1POLBCCR3SIGMAR1CYP3A4 | |
| SCHEMBL12023243 | 0.84 | OPRL1 (0.56) | OPRL1POLBSIGMAR1CYP3A4TP53 | |
| SCHEMBL2514218 | 0.84 | OPRL1 (0.56) | OPRL1POLBOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| EP-2104677-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1531816-B1 | SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | LUNDBECK & CO AS H (DK) | 2009-01-21 | — | — | EP | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-7335665-B2 | Spirocyclic piperidines as MCH1 antagonists and uses thereof | H - LUNDBECK A/S (DK) | 2008-02-26 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060173027-A1 | Spirocvclic piperidines as mch1 antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1531816-A4 | SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | LUNDBECK & CO AS H (DK) | 2005-12-28 | — | — | EP | disclosed |
| CN-1668300-A | Spirocyclic piperidines as MCH1 antagonists and uses thereof | LUNDBECK & CO AS H (DK) | 2005-09-14 | — | — | CN | disclosed |
| EP-1531816-A1 | SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | H. Lundbeck A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004004714-A1 | SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2004-01-15 | — | — | WO | disclosed |
| US-3985889-A | 1,3-DIHYDROSPIRO(ISOBENZOFURAN); ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962259-A | TRANQUILIZERS, ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | OPRL1 131/4885POLB 4470/4885OPRM1 286/4885 |
| US-20060173027-A1 | Spirocvclic piperidines as mch1 antagonists and uses thereof | MCHR1, MCHR2, CRHR1 | OPRL1 12/4885POLB 4835/4885OPRM1 86/4885 |
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885POLB 3327/4885OPRM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.